![](https://stockhead.com.au/wp-content/uploads/2025/02/GettyImages-1304677288-1200x675-1.jpg)
Health Check: Percheron ‘closes the book’ on failed childhood rare disease program
Percheron has detailed why its Duchenne muscular dystrophy trial flopped – and why it needs to find a new drug candidate Imugene’s multiple oncology and inflammation programs aren’t helping its valuation Impedimed and Micro-X raise funds and Alterity is …